Financials in USD. Standardized financial statements.
A compact view of how CytomX Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $76.20M | $138.10M | $101.21M | $53.16M | $37.31M | $68.43M | $57.49M | $59.50M | $71.62M | $15.04M |
| Revenue Growth? | -44.8% | +36.4% | +90.4% | +42.5% | -45.5% | +19.0% | -3.4% | -16.9% | +376.1% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $76.20M | $138.10M | $101.21M | $53.16M | $37.31M | $68.43M | $57.49M | $59.50M | $71.62M | $15.04M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $98.56M | $113.11M | $107.70M | $154.50M | $153.35M | $148.97M | $168.38M | $137.38M | $117.88M | $74.63M |
| Operating Income? | -$22.36M | $25.00M | -$6.48M | -$101.33M | -$116.04M | -$80.54M | -$110.89M | -$77.87M | -$46.26M | -$59.59M |
| EBITDA? | -$20.99M | $26.76M | -$4.31M | -$98.89M | -$113.34M | -$77.97M | -$100.06M | -$75.99M | -$41.97M | -$57.85M |
| Income Before Tax | -$17.13M | $32.09M | $3.32M | -$99.32M | -$115.87M | -$50.91M | -$102.67M | -$70.30M | -$43.61M | -$58.92M |
| Income Tax Expense | $238,000 | $224,000 | $3.89M | $0 | $0 | $13.91M | -$427,000 | $14.30M | -$513,000 | -$19,000 |
| Net Income? | -$17.37M | $31.87M | -$569,000 | -$99.32M | -$115.87M | -$64.82M | -$102.24M | -$84.60M | -$43.10M | -$58.90M |
| EPS? | $-0.15 | $0.38 | $-0.01 | $-1.48 | $-1.26 | $-0.71 | $-2.26 | $-2.03 | $-1.16 | $-1.63 |
| Diluted EPS? | $-0.15 | $0.38 | $-0.01 | $-1.48 | $-1.26 | $-0.71 | $-2.26 | $-2.03 | $-1.16 | $-1.63 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality